Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Atrovent (ipratropium)
- Cibinqo (abrocitinib)
Interactions between your drugs
No drug ⬌ drug interactions were found between the drugs in your list. However, this does not necessarily mean no drug interactions exist. Always consult your healthcare provider.
Drug and food interactions
abrocitinib food
Applies to: Cibinqo (abrocitinib)
MONITOR: Smoking during treatment with abrocitinib may increase the risk of major adverse cardiovascular events (MACE) and the risk of developing malignancies. During abrocitinib clinical studies, current or past smokers had an additional increased risk of overall malignancies. Also, abrocitinib may increase patients' risk of MACE, including myocardial infarction, stroke, and cardiovascular death.
Administration of abrocitinib with high-fat, high-calorie food increased abrocitinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 29% and 26%, respectively, and prolonged the time to reach Cmax by 2 hours. These changes are not considered clinically relevant.
MANAGEMENT: Caution is advised if abrocitinib is prescribed to current or past smokers. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. The manufacturer recommends discontinuing abrocitinib in patients that have experienced a myocardial infarction or stroke. Abrocitinib may be taken with or without food.
References (1)
- (2022) "Product Information. Cibinqo (abrocitinib)." Pfizer U.S. Pharmaceuticals Group
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Breztri Aerosphere
Breztri (budesonide/glycopyrrolate/formoterol fumarate) is a combination inhaler that may be used ...
Xolair
Xolair injection (omalizumab) is used to reduce the risk of severe food allergy reactions ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Symbicort
Symbicort (budesonide and formoterol) is used to prevent bronchospasm in people with asthma or ...
Singulair
Singulair (montelukast) is used to prevent asthma attacks in adults and children as young as 12 ...
Ventolin
Ventolin is used for asthma, acute, asthma, maintenance, bronchiectasis, bronchospasm prophylaxis ...
Ventolin HFA
Ventolin HFA (albuterol) is used to treat or prevent breathing problems in patients who have asthma ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Breo Ellipta
Breo Ellipta (fluticasone and vilanterol) is used to prevent airflow obstruction or bronchospasm in ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.